NICERITROL REDUCES PLASMA LIPOPROTEIN(A) LEVELS IN PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS

被引：11

作者：

NAKAHAMA, H

NAKANISHI, T

UYAMA, O

SUGITA, M

MIYAZAKI, M

YOKOKAWA, T

OKAMURA, K

TANAKA, Y

SHIRAI, D

机构：

[1] Fifth Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya

[2] Kansai Rosai Hospital, Department of Medicine, Amagasaki

[3] Amagasaki Mikami Clinic, Amagasaki

[4] Osaka Koseinenkin Hospital, Department of Medicine, Osaka

来源：

RENAL FAILURE | 1993年 / 15卷 / 02期

关键词：

D O I：

10.3109/08860229309046151

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Lp(a) is an LDL-like lipoprotein carrying the apoprotein(a) glycoprotein and has recently been recognized to be an independent risk factor for coronary heart disease. We studied plasma Lp(a) levels in 40 patients undergoing maintenance hemodialysis (24 male, 16 female; aged 16-83 years). Fasting plasma Lp(a) levels were measured by an enzyme-linked immunosorbent assay. The median value of plasma Lp(a) concentrations in hemodialysis patients was significantly higher than that of the normal volunteers (26.0 +/- 2.7 vs. 10.8 +/- 3.7 mg/dL, p < .05). Lp(a) levels did not correlate with age, duration of hemodialysis, total cholesterol, triglyceride, HDL cholesterol, or LDL cholesterol. The 11 patients whose plasma Lp(a) concentrations exceeded 20 mg/dL received niceritrol, a prodrug of nicotinic acid, at a dosage of 500 mg t.i.d. for 4 weeks. The plasma Lp(a) levels were significantly lower after 4 weeks of treatment (38.3 +/- 4.2 vs. 31.5 +/- 3.2 mg/dL, p < .01).

引用

页码：189 / 193

页数：5

共 17 条

[1]

Berg K., A new serum type system in man—the LP system, Acta Pathol Microbiol Scand, 59, pp. 369-389, (1963)

[2]

Murai A., Miyahara T., Fujimoto K.N., Matsuda M., Kameyama M., Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction, Atherosclerosis, 59, pp. 199-204, (1986)

[3]

Utermann G., The mysteries of lipoprotein(a), Science, 246, pp. 904-910, (1989)

[4]

Mbewu A., Durrington P.N., Lipoprotein(a): Structure, properties and possible involvement in thrombogenesis and atherogenesis, Atherosclerosis, 85, pp. 1-47, (1990)

[5]

Lundin A.P., Adler A.J., Feiroch A.V., Maintenance hemodialy-sis: Survival beyond the first decade, J Am Med Assoc, 244, pp. 38-40, (1980)

[6]

Ritz E., Augustin J., Bommers J., Grasso A., Haberbosch W., Should hyperlipidemia of renal failure be treated, Kidney Int., 28, S17, pp. 584-587, (1985)

[7]

Ponticelli C., Barbe G., Cataluppi A., Donati C., Annoni G., Bran-cacci D., Lipid abnormalities in maintenance dialysis patients and renal transplant recipients, Kidney Int., 13, pp. 572-578, (1978)

[8]

Papadopolus N.M., Borer W.Z., Elin R.J., Diamond L.H., An abnormal lipoprotein in the serum of uremic patients maintained on chronic hemodialysis, Ann Int Med, 92, pp. 634-635, (1980)

[9]

Albers J.J., Cabana V.G., Warnick G.R., Hazzard W.R., Lp(a) lipoprotein: Relationship to sinking pre-β lipoprotein, hyperli-poproteinemia and apolipoprotein B, Metabolism, 24, pp. 1047-1054, (1975)

[10]

Vessby B., Kostner G., Lthell H., Thomis J., Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a), Atherosclerosis, 44, pp. 61-91, (1982)

← 1 2 →